Vascular dementia: European perspectives

Area of Science:

• Neurology
• Clinical Trials
• Geriatrics

Background:

• Vascular dementia (VaD) is a leading cause of cognitive impairment globally, necessitating effective therapeutic strategies.
• Current research highlights the importance of VaD as a significant target for drug development in dementia.
• Methodological challenges in VaD trials necessitate distinct approaches compared to Alzheimer disease (AD) trials.

Purpose of the Study:

• To outline methodological considerations for vascular dementia (VaD) clinical trials.
• To adapt European Medicines Agency (EMEA) guidelines for AD symptomatic treatments to VaD trials.
• To emphasize secondary prevention strategies for VaD due to its link with cerebrovascular diseases.

Main Methods:

• Review and adaptation of existing EMEA guidelines for Alzheimer disease (AD) symptomatic treatments for VaD trials.
• Analysis of methodological differences between VaD and AD trials.
• Focus on secondary prevention and symptom stabilization through vascular risk factor control.

Main Results:

• No explicit VaD trial guidelines exist, but AD guidelines offer a framework for symptomatic treatments.
• Secondary prevention holds greater promise for VaD than AD due to identifiable and controllable vascular risk factors.
• Symptomatic VaD drugs require evaluation within a context of rigorous vascular risk factor management.

Conclusions:

• Clinical trials for vascular dementia (VaD) should incorporate specific methodological adaptations, drawing from Alzheimer disease (AD) guidelines.
• Emphasis on secondary prevention and stabilization of VaD symptoms through vascular risk factor control is paramount.
• Future VaD trials, particularly for secondary prevention, should extend to at least one year to assess long-term efficacy.